Patents by Inventor Fionn O'Hara
Fionn O'Hara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11242349Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.Type: GrantFiled: May 1, 2020Date of Patent: February 8, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Fionn O'Hara
-
Publication number: 20210387999Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, X, R1, R2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: May 20, 2021Publication date: December 16, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Bernd KUHN, Uwe GRETHER, Benoit HORNSPERGER, Hans RICHTER, Carsten KROLL, Katrin GROEBKE ZBINDEN, Fionn O'HARA, Didier ROMBACH, Marius Daniel Rinaldo LUTZ
-
Publication number: 20210277020Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.Type: ApplicationFiled: February 11, 2021Publication date: September 9, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Lilli ANSELM, Joerg BENZ, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dominik HEER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Fionn O`HARA, Hans RICHTER
-
Publication number: 20210269452Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.Type: ApplicationFiled: May 9, 2021Publication date: September 2, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
-
Patent number: 11034699Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.Type: GrantFiled: December 14, 2018Date of Patent: June 15, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
-
Publication number: 20210107920Abstract: The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R20 to R23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 18, 2020Publication date: April 15, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dennis Jul HANSEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Fionn O'HARA, Hans RICHTER, Martin RITTER, Satoshi TSUCHIYA, Rui CHEN
-
Publication number: 20210107921Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, Q, U, V, W, X, Z, m, n, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 21, 2020Publication date: April 15, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Steven Paul HANLON, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Martin KURATLI, Guofu LIU, Fionn O`HARA, Hans RICHTER, Martin RITTER
-
Publication number: 20210094972Abstract: The invention provides new heterocyclic compounds having the general formulae (Ia) and (Ib) wherein A, B, and L are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 22, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
-
Publication number: 20210094943Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and RI to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 10, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
-
Publication number: 20210094973Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L1, X, m, n and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 22, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER
-
Publication number: 20210094971Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, X, R1, R2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 4, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O`HARA, Hans RICHTER
-
Publication number: 20200308190Abstract: The invention provides new heterocyclic compounds having the general formula wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: April 9, 2020Publication date: October 1, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER, Didier ROMBACH, Martin KURATLI
-
Publication number: 20200299277Abstract: The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: March 23, 2020Publication date: September 24, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Uwe GRETHER, Benoit HORNSPERGER, Bernd KUHN, Hans RICHTER, Buelent KOCER, Fionn O'HARA, Martin RITTER, Satoshi TSUCHIYA, Ludovic COLLIN, Simon E. JOHNSON, Charles BELL
-
Publication number: 20200291033Abstract: The present invention relates to compounds of formula I wherein L is a bond, a triple bond, —C(O)NH— or —NHC(O)—; R1 is phenyl or a five or six-membered heteroaryl group, optionally substituted by lower alkyl, lower alkyl substituted by halogen or lower alkoxy substituted by halogen; R2 is fluoro; R3 is fluoro or chloro; R4 is hydrogen, lower alkyl, halogen, lower alkyl substituted by hydroxy, S(O)2CH3, or is a five or six-membered heteroaryl group or a heterocycloalkyl group, which are optionally substituted by lower alkyl, hydroxy or ?O; R5 and R6 are both methyl and the dotted line is a bond, or R5 and R6 are both methyl and the dotted line is nothing, or one of R5 and R6 is hydrogen and the other is methyl, and the dotted line is nothing; or to a pharmaceutically acceptable salt or acid addition salt, to all possible tautomeric forms, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.Type: ApplicationFiled: February 13, 2020Publication date: September 17, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Georg JAESCHKE, Fionn O'HARA, Eric VIEIRA
-
Publication number: 20200255440Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.Type: ApplicationFiled: May 1, 2020Publication date: August 13, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA
-
Publication number: 20190144458Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.Type: ApplicationFiled: January 17, 2019Publication date: May 16, 2019Applicant: Hoffmann-La Roche Inc.Inventors: BARBARA BIEMANS, GEORG JAESCHKE, ANTONIO RICCI, DANIEL RUEHER, FIONN O'HARA
-
Publication number: 20190119290Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.Type: ApplicationFiled: December 14, 2018Publication date: April 25, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
-
Patent number: 10189848Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.Type: GrantFiled: January 12, 2018Date of Patent: January 29, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
-
Patent number: 10065956Abstract: The present invention relates to compounds that may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2. Compounds of formula I are representative, where substituents are defined herein: or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.Type: GrantFiled: September 18, 2017Date of Patent: September 4, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Jean-Marc Plancher, Antonio Ricci, Daniel Rueher, Eric Vieira, Fionn O'Hara
-
Patent number: 10011607Abstract: The present invention relates to compounds of formula I wherein R1 is hydrogen, F or Cl; L is a bond or lower alkylene; R2 is —(CH2)nO-lower alkyl, lower alkyl substituted by halogen, —(CH2)nC(O)O-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, ?O, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by —(CH2)nO-lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or —(CH2)nO-lower alkyl; R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F; Y is CF or CCl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof.Type: GrantFiled: January 10, 2018Date of Patent: July 3, 2018Assignee: Hoffman-La Roche Inc.Inventors: Georg Jaeschke, Fionn O'Hara, Jean-Marc Plancher, Antonio Ricci, Daniel Rueher, Eric Vieira